佰澤醫療(02609.HK)共同發起“腫瘤康復五大處方”倡議書
格隆匯6月26日丨佰澤醫療(02609.HK)公吿，公司旗下太原和平醫院作為中國醫院康復醫學聯合體常務理事單位，於2024年5月31日在中國醫院康復醫學聯合體成立大會上聯合北京大學第三醫院、中國中醫科學院西苑醫院等全國30多家大型醫療機構共同發起「腫瘤康復五大處方」倡議書。並於會後聯合北京大學第三醫院組織全國知名三甲醫院腫瘤、營養、心理、康復專業共計29名專家（包括集團七名專家）起草「腫瘤康復專家共識」，採用「德爾菲法」形成了《腫瘤康復專家共識(2025)》，該專家共識於2025年3月20日獲得國際實踐指南註冊平台註冊證明，2025年5月26日收到中華臨牀醫師雜誌文稿錄用通知，2025年6月23日見刊發表。
腫瘤康復已成為提升患者生存質量、減少治療副作用和促進功能恢復的重要環節。本共識基於全球最新研究與臨牀經驗，明確了腫瘤康復的適用人羣及目標，提出了腫瘤康復的系統評估標準和科學、可行的「五大處方」康復策略。共識強調腫瘤康復應貫穿包括腫瘤治療前的預康復、治療期的康復干預及長期康復，多學科團隊(MDT)在腫瘤康復中應發揮核心作用。本次見刊的中華臨牀醫師雜誌是由中國國家衞生健康委員會主管，中華醫學會主辦的中華醫學會系列期刊之一，被中國科技核心期刊目錄及北大核心期刊目錄收錄，是國內最具影響力的醫學科技期刊之一。
董事會認為，堅持推行包括運動處方、營養處方、藥物處方、心理處方和舒緩處方在內的腫瘤康復「五大處方」策略，是集團腫瘤全週期業務的重要環節。集團和其他第三方專家發起聯合起草的《腫瘤康復專家共識》在中華醫學會系列雜誌發佈，表明集團腫瘤康復業務得到了相應行業的充分認可，是集團與行業內其他醫療機構的核心競爭力差異所在，展示集團對自身業務展望及前景充滿信心，最終會為公司帶來裨益及為股東創造價值。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
